XBiotech Inc. (XBIT) Reaches $6.49 52-Week High; Arca Biopharma (ABIO) Shorts Up By 11.12%

XBiotech Inc. (NASDAQ:XBIT) Logo

Arca Biopharma Inc (NASDAQ:ABIO) had an increase of 11.12% in short interest. ABIO’s SI was 321,800 shares in January as released by FINRA. Its up 11.12% from 289,600 shares previously. With 1.07 million avg volume, 0 days are for Arca Biopharma Inc (NASDAQ:ABIO)’s short sellers to cover ABIO’s short positions. It closed at $0.44 lastly. It is down 59.24% since January 30, 2018 and is downtrending. It has underperformed by 59.24% the S&P500.

The stock of XBiotech Inc. (NASDAQ:XBIT) hit a new 52-week high and has $7.01 target or 8.00% above today’s $6.49 share price. The 9 months bullish chart indicates low risk for the $232.42M company. The 1-year high was reported on Jan, 30 by Barchart.com. If the $7.01 price target is reached, the company will be worth $18.59M more. The stock increased 3.65% or $0.23 during the last trading session, reaching $6.49. About 63,140 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 30, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – Nasdaq” on January 29, 2019, also Seekingalpha.com with their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019, Globenewswire.com published: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” on August 10, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” published on October 31, 2018 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” with publication date: December 03, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $232.42 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *